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Abstract  
Multiple neurodegenerative disorders with tau pathology are characterized by the loss 
of memory and cognitive decline that can be associated with other symptoms including 
olfactory alterations that are often regarded as an early symptom of the diseases. Here we 
have investigated whether olfactory dysfunction is present in the P301S human tau 
transgenic mice and if it is associated to tau pathology. Progressive tauopathy and 
neurodegeneration were noticeable in the olfactory bulb and piriform cortex at early age in 
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the P301S human tau transgenic mice and olfactory sensitivity for social or non-social 
odours was significantly impaired at 3 months of age, when the piriform cortex-dependent 
odour-cross habituation was also disrupted. The olfactory alterations in the P301S tau 
transgenic mouse line provide an in vivo system where to test mechanism-based therapies 
for the common and yet untreatable tauopathies. 
 
Introduction 
Alzheimer's disease (AD) is the most common neurodegenerative disorder yet there is no 
effective treatment for it. Neurofibrillary tangles consisting of hyperphosphorylated tau 
protein are one of the major neuropathological hallmarks in AD (Spillantini & Goedert, 2013). 
The spatiotemporal progression of tau pathology correlates well with the progression of 
neurodegeneration (Braak & Braak, 1991) and dementia (Giannakopoulos et al., 2003; 
Bierer et al., 1995; Petersen et al., 2006). The topographical distribution of neurofibrillary 
tangles is used for the pathological diagnosis of AD (Braak & Braak, 1991).  
Olfactory dysfunction is one of the earliest symptoms of AD, often preceding the classical 
cognitive impairments by many years (Hawkes, 2003; Forster et al., 2010). It has been 
reported that olfactory perceptual deficits are correlated with a higher risk of developing mild 
cognitive impairment and severity of cognitive dysfunction, which is also considered a 
prodromal symptom for early diagnosis of AD (Wilson et al., 2009; Walla et al., 2011).  In 
many post-mortem studies of AD patients, tau pathology has been described in the olfactory 
system such as the olfactory bulb, the anterior olfactory nucleus and the piriform cortex 
(Attems et al., 2014; Saiz-Sanchez et al., 2014), that are associated with the Braak staging 
and indicative of a high risk of cognitive decline (Attems & Jellinger, 2006). Non-AD human 
tauopathies such as frontotemporal dementia/Pick’s disease, corticobasal 
degeneration and progressive supranuclear palsy have been reported to show 
olfactory alterations associated with progression of the pathology, leading to 
olfactory dysfunction (Yoshimura, 1988; Luzzi et al., 2007; Pardini et al., 2009; Silveira-
Moriyama et al., 2010).  
We hypothesized that the olfactory neural system can be affected by tau pathology in our 
transgenic P301S tau mice, a model of tau aggregation and we decided to investigate 
whether tau pathology correlated with olfactory dysfunction and neurodegeneration. 
The P301S tau mice express human mutant P301S tau under the control of the murine 
Thy1.2 promoter. In humans, the P301S mutation in the MAPT gene leads to a 
progressive tauopathy, causing frontotemporal dementia (Bugiani et al., 1999). This 
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mouse model presents progressive tau pathology until the age of 5-6 months when 
the mice have to be culled due to their motor phenotype (Allen et al., 2002; Delobel et 
al., 2008). The presence of olfactory dysfunction related to tau pathology and related 
neurodegeneration would provide an in vivo model where one can test mechanism-based 
therapies for the common and yet untreatable tauopathies. 
Materials and Methods 
Animals 
Homozygous transgenic P301S (Tg P301S) tau (Allen et al., 2002) and C57BL/6S (C57BL/6 
OlaHsd; Harlan, UK) control mice were used for this study. Only male mice were used in the 
experiments. All procedures were performed in accordance with the UK Home Office 
Regulations for the Care and Use of Laboratory Animals and the UK Animals (Scientific 
Procedures) Act 1986 and were approved by the Cambridge University local ethical 
committee.  
Immunohistochemistry 
Sample preparations and the general procedures of immunostaining have been described 
previously (Yang et al., 2015). Thirty µm free floating sections were immunostained with the 
monoclonal anti-phospho tau antibody AT8 (1:1000, Innogenetics) or NeuN antibody (1:400, 
Millipore). The immunostaining was visualized with an avidin-biotin system (Vectastain®ABC 
kit; Vector Laboratories) and 3′,3′diaminobenzidine as the chromogen (DAB kit; Vector 
Laboratories). Tissue sections were mounted on glass slides and examined using a light 
microscope and photographed using a digital camera (Leica DM6000 Microsystems). The 
characteristics of tau pathology that were determined in transgenic P301S tau mice were 
compared to age-matched wild type control mice at 1, 2 and 5 months of age (C57BL/6S, 
Harlan laboratory).  The time course of neuronal cell loss was investigated in Tg P301S tau 
mice and age-matched wild type control mice at 1, 3 and 5 months of age (1 month; Control 
n=3-6, P301S n=3-6; 3 months; Control n=3-4, P301S n=3-4; 5 months; Control n=4-7, 
P301S n=6-7). 
Stereology 
Stereological techniques were used in quantifying cells, and the counts were made in 
2-dimensional space. For cortical counting, a total number of 5 sections per animal taken 
every 12th brain sections were used after immunostaining with NeuN antibody. NeuN-
positive neurons were counted in layer I-II and layer III of the piriform cortex using the optical 
fractionator method of stereological counting with commercially available stereological 
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software (Stereo Investigator; MBF Bioscience) as previously described (Yang et al., 2015). 
The piriform cortex was divided into anterior and posterior divisions and the lateral 
olfactory tract (LOT) was used as a landmark (Ekstrand et al., 2001). The total number 
of mitral cells in the olfactory bulb was similarly estimated using Nissl staining to identify the 
cap-shaped cell soma in the mitral cell layer. Sample counting windows were randomly 
identified using the computer software after setting the parameters for the counting frame 
and the counting grid at 40 µm x 40 µm and 200 µm x 200 µm (cortex), 60 µm x 60 µm and 
120 µm x 120 µm (olfactory bulb), respectively. The number of cells in each window was 
counted using a 20x objective. 
 
Olfactory sensitivity test 
For consistency only male mice were investigated, and they were singly housed for at least 2 
weeks prior to the test and their home cages were used as a testing chamber. The mice 
were repeatedly exposed to filter paper saturated with mineral oil 5 times (habituation). Each 
presentation lasted for 2 min with an interval of 1 min among presentations. The filter paper 
with olfactory stimulus diluted in mineral oil (1-butanol and vanilla) or distilled water (female 
urine) was hung on the grid of their home cage. Female urine was pooled from five non-
cagemates. Urine was collected by holding the mouse by the scruff of the neck and 
stored in 50 µl aliquots at -80 C till use. The olfactory stimulus was presented in an 
ascending order of concentration. The concentration of odour at which the animals showed 
snout-oriented sniffing within 1 cm from the origin of the odour was recorded. Tg P301S tau 
mice and wild type control mice were tested at 1 month (1-butanol: Control n=5, P301S n=7, 
vanilla: Control n=5, P301S n=6), 3 months (1-butanol: Control n=7, P301S n=7, vanilla: 
Control n=6, P301S n=5) and 5 months (1-butanol: Control n=13, P301S n=10, vanilla: 
Control n=7, P301S n=6) of age.  Four month-old animals were used to test the behaviour 
for the social odour (female urine: Control n=17, P301S n=12). 
 
Odour cross-habituation test  
The olfactory memory was tested in 3 month-old P301S and control mice using an odour 
cross-habituation test, which was modified from the previously published protocol (Wesson 
et al., 2010). Odours used in this study (n=3; limonene, pentanol and heptanone; Sigma-
Aldrich) were diluted 1x 10-3 into mineral oil and 20µl of odour was applied to 3MM filter 
paper (15cm x 1.5cm; Whatman). This test was performed during the dark phase of 12 hour 
light/dark cycle under a red light in order to minimise any visual attraction or anxiety during 
the test. Odours were presented three successive times for 2 minutes, separated by 30 
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seconds intervals by hanging the filter paper to the cage grid. The presentations of odours 
were counterbalanced in testing groups. The time for active investigation of odours was 
defined as snout-oriented sniffing within 1cm of the origin of the odour. The raw investigatory 
values were normalised to the maximum investigatory duration during three trials for each 
odour. Discrimination index was calculated by subtracting the normalised duration of the 
previous trial odour investigation (3rd trial) from that of the following 1st trial presentation. 
Statistical analyses 
Statistical analyses were performed by unpaired two-tailed t tests using GraphPad Prism 
version 5.0 and one-way ANOVA was used for group analysis. Results of odour-cross 
habituation test were analyzed in SAS v9.1 by a three-way repeated measure ANOVA 
implemented in a mixed model using Genotype as the between-subject factor and 
Trial and Odour as within-subject factors, respectively. Power transformation was 
applied on residuals to obtain normality. Post-hoc analysis was conducted using 
Tukey–Kramer to correct for multiple comparisons. Correlation coefficient analysis 
was performed in MATLAB R2015b using the following equation:  
 
Where  and  are the means of the groups A and B;  and  are the standard 
deviations of A and B. When the p value was 0.05 or less it was regarded as 
statistically significant.  
Results 
Early appearance of hyper-phosphorylated tau in olfactory system of Tg P301S tau 
mice  
Tau pathology in olfactory structures including the olfactory bulb and piriform cortex was 
investigated by immunohistochemistry in homozygous Tg P301S tau mice at 1, 2 and 5 
months of ages using monoclonal antibody AT8 which detects hyper-phosphorylated tau 
(Fig 1). Progressive tauopathy in other parts of the nervous system such as cortex and 
spinal cord has been well documented throughout the life span of Tg P301S tau mice but 
tauopathy in olfactory structures has not been thoroughly described. In the olfactory bulb 
of Tg P301S tau mice the mitral cell layer was dominantly affected by tau pathology 
already at 1 month of age, displaying neuronal cell bodies containing hyperphosphorylated 
tau protein and abnormal dystrophic neurites (Fig 1A-D). No staining was observed with AT8 
antibody in age-matched wild type control mice (Fig 1E). The mitral cell layer was more 
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severely affected at 2 months of age in P301S tau mice, showing more neuronal cell bodies 
and the processes were intensely stained by AT8 antibody (Fig 1F-I). At 2 months of age 
hyper-phosphorylated tau also appeared in the frontal association cortex. This was not 
consistent at 1 month of age (Fig 1J). At 5 months of age, P301S tau mice presented AT8 
staining throughout all layers of the olfactory bulb including the granule cell layer, mitral cell 
layer and external plexiform layer (Fig 1K-M and P). A small proportion of tuft cells, as 
well as cells in the anterior olfactory nucleus were also labeled with AT8 antibody at 5 
months of age (data not shown). The frontal association cortex was heavily stained with 
many AT8-positive neurons, consistent with progressive tauopathy found throughout the 
cortex of 5 month-old P301S mice (Fig 1N) (Delobel et al., 2008). No AT8 immunostaining 
was observed in age-matched wild type control mice also at 2 and 5 months of age (Data not 
shown). These observations indicate that hyperphosphorylated tau appeared early in the 
olfactory bulb in Tg P301S human tau mice. These findings in P301S tau mice thus 
reflect in part the neuropathology in the human AD brain, showing neurofibrillary 
tangles in all layers of the olfactory bulb including the mitral cell layer and external 
plexiform layer (Kovacs et al., 1999). However there was no significant neuronal 
reduction in mitral cell counts in the olfactory bulb compared to aged-matched 
control mice at the time of observation (5 months, Control 3.1x104 ± 1612 vs P301S 
2.9x104 ± 1425, unpaired t-test, p>0.05). 
  
Progressive neurodegenerative tauopathy in the piriform cortex of Tg P301S mice 
The most affected area in the olfactory bulb seemed to be the mitral cell layer and external 
plexiform layer, which consist of primarily glutamatergic neurons that project to the main 
olfactory cortex such as piriform cortex. The excitatory signals are transmitted to the 
amygdala and hippocampus via the piriform cortex. Anatomically, the piriform cortex locates 
at the base of the latero-ventral area of the rodent brain and consists of two subdivisions, the 
anterior piriform cortex (aPC) and the posterior piriform cortex (pPC) (Fig 2A). The anterior 
piriform cortex was distinguished from the posterior cortex based on the division 
made where the lateral olfactory tract (LOT) disappears on the ventral surface of the 
brain (Fig 2A)(Ekstrand et al., 2001).  
Progressive tau pathology was detected in the piriform cortex with AT8 antibody at 1 month, 
3 months and 5 months of age in Tg P301S tau mice (Fig 2A-F). The AT8-postive neurons 
were mostly found in layer II while they were sparse in layer III of the piriform cortex. They 
were more abundant in the posterior part than the anterior part throughout the ages tested 
(Fig 2). At 5 months of age P301S tau mice revealed severe tau pathology with intense AT8 
staining in the piriform cortex (Fig 2C and F). This was associated with neuronal cell loss as 
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shown by stereological quantification of NeuN-positive neurons in the piriform cortex (Fig 3). 
The quantification was separately performed in layer I-II and layer III in the anterior and 
posterior piriform cortex at 1, 3 and 5 months of age and comparing P301S tau and wild type 
control mice (Fig 3E and J). The neuronal loss in the piriform cortex was noticeable from the 
age of 3 months in P301S tau mice, showing a 25% reduction compared to age-matched 
control mice (Fig 3E and J). Interestingly, the progression of neuronal loss did not proceed in 
the same manner in the anterior and posterior piriform cortex. While no further reduction 
was observed in layer I-II in the anterior part, an increase from 25% to 42% was observed in 
the same layers in the posterior piriform cortex at 5 months of age (Fig 3E and J).  
The piriform cortex layer III was in general, less affected by tau pathology compared to layer 
II, since AT8-positive neurons were sparsely found in layer lll even at the advanced stage of 
disease (Fig 3A-D). Moreover, no significant neuronal loss was found in layer lll of the 
anterior piriform cortex at any age tested, whilst 13% of neuronal loss was found in layer III 
of the posterior piriform cortex in mice at 5 months of age. Immunohistochemistry using 
NeuN antibody showed that layer II and III in the posterior piriform cortex became thinner 
due to the neurodegeneration in the P301S tau mice compared to the control mice at 5 
months of age (Fig 3F-I). However, the corresponding area in the anterior piriform cortex 
was largely intact (Fig 3A-D). The neuronal loss was more pronounced in the posterior 
piriform cortex compared to the anterior part and suggests that the posterior piriform cortex 
could be more vulnerable to neuropathological changes as seen also in human tauopathy 
(Saiz-Sanchez et al., 2014). Only a low level of AT8-postive staining was observed in 
other olfactory structure such as the olfactory tubercles (data not shown). 
Impairment of olfactory functions in Tg P301S tau mice 
Olfactory sensitivity 
The presence of hyperphosphorylated tau and subsequent reduction in neuronal cell counts 
in the piriform cortex lead us to question whether the Tg P301S tau mice had normal 
olfactory functions. Therefore, we tested two different aspects of olfaction, olfactory 
sensitivity and odour-cross habituation behaviour. 
Olfactory sensitivity was performed using non-social odours (e.g. 1-butanol and vanilla) and 
social odour (e.g. female urine) using the ascending staircase method to test P301S tau 
mice and age-matched control mice (Fig 4A-D). Tg P301S tau mice showed a significant 
reduction in olfactory sensitivity towards both social and non-social odours at 3 months of 
age. For non-social odour using 1-butanol, which is a less favoured scent, P301S tau mice 
presented a clear deficit at 5 months of age (Fig 4A, unpaired t-test, ***p<0.001) whilst with 
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non-social odour vanilla, which is a neutral scent, the P301S tau mice showed progressive 
impairment in odour sensitivity starting at 3 months (unpaired t-test, *p<0.05) and 
established a more robust deficit at 5 months of age (Fig 4B, unpaired t-test, ***p<0.001). In 
order to confirm the de-sensitised olfaction, male P301S tau mice were exposed to female 
urine, which is generally a strong social odour for male mice. Olfactory sensitivity declined 
dramatically in P301S tau mice at the age of 4 months (Control 21 ± 0.39 vs P301S 14.2 ± 
2.1, unpaired t-test, ***p<0.001, Fig 4C). Olfactory exploratory behaviour clearly 
demonstrated that P301S tau mice displayed no significant explorative behaviour towards 
the weak stimulus represented by highly diluted urine (0.0001% v/v) compared to wild 
type control mice (Control 7.1 ± 2.2 vs P301S 1.16 ± 0.47, unpaired t-test, *p<0.05). 
Whereas the P301S tau mice spent the same amount of time exploring high concentration of 
female urine (1% v/v) compared to the wild type control mice (Fig 4D). 
Odour-cross habituation was disrupted in Tg P301S tau mice  
Neuronal cell loss and the heavy load of tau pathology were significant in the piriform cortex, 
especially in its posterior part in the P301S tau mice (Fig 3). Therefore the Tg P301S tau 
mice with their age-matched controls were subjected to the odour-cross habituation test, 
which has been suggested to be a piriform cortex-dependent task for rodents (Linster et al., 
2009). When the wild type control mice with intact olfactory function were repeatedly 
exposed to the same scent their olfactory explorative behaviour was dramatically reduced at 
the second and third exposure to the scent (habituation status) and when a novel scent was 
introduced to them they showed a high level of explorative behaviour to the scent (dis-
habituation status) (Fig 4E). Three different odours were counterbalanced for testing each 
animal (e.g. limonene, heptanone, pentanol). There was a significant genotype effect in 
response to new odour exposure (F2, 48=4.61, p=0.015). This was supported by the 
discrimination index (Control 0.72 ± 0.07 vs P301S 0.14 ± 0.19, p=0.043), which 
indicates that the normal pattern of odour-cross habituation was disturbed in the Tg 
P301S tau mice (Fig 4E). P301S tau mice showed an incomplete habituation for each 
odour and compromised dis-habituation and were less able to discriminate a novel 
scent from the previously exposed scent (Fig 4E). In order to compare the similarity of 
odour-cross habituation between the wild type control and the Tg P301S tau mice, we 
performed a correlation coefficient analysis and found no significant association 
between the two genotypes (r=0.61, p>0.05). In line with this, a three-way repeated 
measure ANOVA was used to examine the effect of odour, trial, and genotype on the 
time for active investigation and there was a significant three-way interaction (F4, 
48=2.99, p=0.028). This abnormal odour-cross habituation behaviour is also indicative of 
impairment in olfactory memory, which can be attributed to tau pathology and neuronal 
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dysfunction in the piriform cortex, amygdala and perirhinal/entorhinal cortex present in the 
P301S tau mice. 
Discussion  
There are several studies reporting that the olfactory neural circuit is affected very early on 
and could be a disease-starting point in major brain disorders such as AD and PD (Doty, 
2012; Alves et al., 2014). Since the loss of olfactory function is one of the common 
symptoms in neurological brain disorder and often regarded as a preclinical symptom in 
demented diseases, this area has been also considered as a therapeutic target (Wilson et 
al., 2009; Forster et al., 2010; Alves et al., 2014). This study presents an in vivo model of 
human tauopathy with olfactory neural circuitry displaying tau aggregation, neural 
degeneration and olfactory dysfunction. In an animal model overexpressing a mutated form 
of the human amyloid-beta precursor protein, a correlation between the extracellular loads of 
amyloid and the olfactory deficit assessed by olfactory cross-habituation test has been 
described (Wesson et al., 2010). Similarly, in a transgenic mouse overexpressing human 
tau, T1-3RT mouse line, an olfactory functional deficit has been shown using olfactory 
habituation test (Macknin et al., 2004). Our studies with the Tg P301S tau mice 
overexpressing human mutant tau (4R0N P301S) under the murine Thy1.2 promoter, 
suggest that their olfactory system is vulnerable to hyperphosphorylated tau and it could be 
one of the brain regions targeted early on by tau pathology.  
Our immunohistochemical studies with the anti-hyperphosphorylated tau antibody AT8 in Tg 
P301S tau mice, show that the mitral cells are the most affected neuronal population in the 
olfactory bulb, with intracellular tau deposits in the soma, as well as dystrophic neurites 
projecting through in the external plexiform layer. The synaptic processing in the external 
plexiform layer, between the glomerular layer and the mitral cell layer is known to be critical 
in the piriform cortex for perception of odour (Wilson et al., 2014). Therefore the early tau 
hyperphosphorylation in these areas of the olfactory bulb could initiate the synaptic 
dysfunction that progresses together with neuronal cell loss in the piriform cortex of the Tg 
P301S tau mice. It is possible that the Thy 1.2 promoter drives higher expression in 
mitral cells in this P301S tau model, however, neurofibrillary tangles have been 
described in mitral cells in Alzheimer's disease and also in normal aging (Kovacs et 
al., 1999), indicating that these cells are susceptible to develop tau pathology also in 
human brain. 
Functional impairments in odour sensitivity and discrimination became more severe when 
the neuronal cell loss in the piriform cortex co-exists with a synaptic deficit in the olfactory 
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bulb. The glutamatergic mitral cells mainly project to the primary cell layer of the piriform 
cortex (layer II), where discrete neurodegeneration and tau pathology was observed, 
reflecting the selective vulnerability of different neuronal populations in this mouse model of 
human tauopathy. It was reported that strong afferent inputs from olfactory bulb are 
found in layer ll principal neurons in the piriform cortex, whereas neurons in layer lll 
received considerably more intra-cortical inhibition (Large et al., 2016). In fact, 
different subsets of inhibitory GABAergic interneurons have been described in the 
piriform cortex. The interneurons in layer II express predominantly calretinin and 
vasoactive intestinal peptide, whilst those in layer III mainly express calbindin and 
parvalbumin (Suzuki & Bekkers, 2007).  
Moreover, the neurodegeneration seemed to progress more rapidly in the posterior piriform 
cortex compared to the anterior part, suggesting that the posterior piriform cortex could be 
more vulnerable to the neuropathological changes occurring in human tauopathy. The 
impaired odour quality coding, leading to olfactory deficits in AD correlates with neurological 
lesions in the posterior piriform cortex based on functional magnetic resonance imaging 
performed during odour cross-habituation test (Li et al., 2010). Recent neuropathological 
studies in brains of AD patients have also demonstrated the preferential vulnerability of layer 
II among the three layers of piriform cortex and of the posterior piriform cortex (in human 
brain, temporal lobe of piriform cortex) for AD’s pathology (Saiz-Sanchez et al., 2014). The 
posterior piriform cortex presents complex connections to major adjacent cortices including 
perirhinal cortex, entorhinal cortex and amygdala, and these are the regions in the brain 
most affected in AD. The 40% reduction in NeuN positive neuronal cells in the piriform cortex 
was more extensive than what we have observed in other cortices of P301S tau mice such 
as the motor cortex (Hampton et al., 2010) and the perirhinal cortex, where approximately 
25% of neuronal loss was found at 5 months of age, presenting an advanced stage of 
pathology in P301S tau mice (Yang et al., 2015).  
The olfactory deficit was present at 3 months of age, in parallel with impaired object 
recognition memory, which is perirhinal cortex-dependent (Yang et al., 2015) and 
declined motor coordination (Scattoni et al., 2010), at the time when hippocampal-
dependent spatial learning was normal in P301S tau mice (Scattoni et al., 2010). The 
object-placement memory, which is also hippocampal-dependent, was not impaired in 
3 month-old P301S tau mice (SY’s unpublished data). Thus, the olfactory dysfunction 
including impaired odour discrimination observed in 3 month-old P301S tau mice are 
likely to be associated with the neurodegenerative tauopathy in the piriform cortex 
than hippocampus.  
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These results together with the early detection of the pathological form of tau protein in the 
olfactory bulb suggest that the olfactory system is more susceptible to tau pathology when 
compared to the other cerebral cortices in the P301S tau mice. In particular the posterior 
piriform cortex of Tg P301S tau mice will be a good model where functional deficits, 
observed also in patients with AD, can be correlated with progressive tau-related 
neurodegeneration. The olfactory tau pathology may contribute to the early alterations of 
olfactory functions that constitute the classical disease symptoms of early AD (Wilson et al., 
2009; Attems et al., 2014). To our knowledge this is the first study on the effect of 
progressive tau pathology and neurodegeneration in the olfactory system and its association 
with olfactory functional impairment. Previous studies had reported on the influence of Aß on 
interneurons in the piriform cortex of APPxPS1 transgenic mice (Saiz-Sanchez et al., 2013). 
Future studies will further examine the different susceptibility of neuronal populations to tau 
pathology in our mouse model of human tauopathy. 
The olfactory system has been of huge interest since olfactory dysfunction is a prodromal 
symptom of many neurodegenerative disorders such as AD and PD. Moreover, the olfactory 
system has been proposed as a potential site for disease propagation, either anterogradely 
or retrogradely, in PD (Hawkes et al., 2007). This means that the olfactory neural circuitry is 
the appropriate target for the early diagnosis or treatment of the diseases. In this report, we 
provide the evidence that the olfactory system of Tg P301S tau mice presents early tau 
pathology, progressive neurodegeneration in the piriform cortex and olfactory 
functional deficits. The olfactory alterations in the P301S tau transgenic mouse line provide 
an in vivo system where to test mechanism-based therapies for the common and yet 
untreatable tauopathies. 
Figure Legends 
Figure 1. Early appearance of hyperphosphorylated tau in the olfactory bulb of Tg P301S 
tau mice. 
Immunostaining with phosphorylation dependent AT8 antibody was performed in the mice at 
1, 2 and 5 months of age to determine the progression of olfactory tau pathology. AT8 
staining in olfactory bulb of (A-D) 1 month-old P301S tau mice (E) 1 month-old wild type 
control mouse (F-J) 2 month-old P301S tau mice (K-P) 5 month-old P301S tau mice. White 
dotted lines define the regions. The boxed areas in A, C, F, H, K and N were enlarged in 
panels B, D, G, I, J, L, M, O and P respectively. GRL: granule cell layer; MCL: mitral cell 
layer; EPL: external plexiform layer; GL: glomerular layer; ONL: olfactory nerve layer; FrA: 
frontal association cortex; Scale bar; 100 µm (A, F); 30 µm (B, D, E, G, I, J, L, M, O, P); 1 
mm (C, H, K, N)  
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Figure 2. Progressive tauopathy in the piriform cortex in Tg P301S tau mice. 
(A) Anatomical illustration of a mouse brain indicating anterior (aPC) and posterior (pPC) 
piriform cortices. Areas indicated by asterisks are the corresponding locations of panels B 
and C. Immunohistochemistry profile of AT8-positive tau pathology at the coronal view of (B) 
aPC, bregma 0.86 mm (C) pPC, bregma -1.46 mm. White dotted line defined the regions of 
aPC and pPC. AT8 staining of tau pathology in aPC (D-F) and pPC (G-I) is shown at 
different ages: 1 month (1M, D, G), 3 months (3M, E, H) and 5 months (5M, F, I). Scale bar; 
1 mm for B-C, 50 µm for D-I. OB: olfactory bulb; LOT: lateral olfactory tract; rf: rhinal fissure.  
 
Figure 3. Progressive neuronal cell loss in the piriform cortex in Tg P301S tau mice. 
Representative images of NeuN staining and quantification of NeuN-positive cells in aPC (A-
E) and pPC (F-J) of 5 months-old mice. Wild type control mice (A, B, F, G) and P301S tau 
mice (C, D, H, I). Panels B, D, G and I are enlarged images of the boxed areas in panel A, 
C, F and H, respectively. The neuronal counts of layer I-II and layer III were performed using 
stereology.  (E) There was a significant decrease, 25% in neurons number in layer I-II of 
aPC at both 3 and 5 month-old P301S tau mice compared to age-matched control mice. (J) 
Progressive neuronal cell loss was observed in pPC of P301S tau mice where a 25% and 
44% reduction in neurons was observed at 3 and 5 months of age respectively compared to 
age-matched control mice. Scale bar; 1 mm for A, C, F, H; 50 µm for B, D, G, I. Layer I-II 
counting: 1M: control n=6, P301S n=6; 3M: control n=4, P301S n=4; 5M: control n=5, P301S 
n=6. Layer III counting: 1M: control n=3, P301S n=3; 3M: control n=3, P301S n=3; 5M: 
control n=4, P301S n=6. White bar: Control, black bar: P301S, *p<0.05, **p<0.01 by two-
tailed t-test analysis.  
 
Figure 4. Olfactory functional deficit in Tg P301S tau mice. 
Olfactory sensitivity test for non-social odours (A) Odour: 1-butanol, 1M: control n=5, P301S 
n=7; 3M: control n=7, P301S n=7; 5M: control n=13, P301S n=10. (B) Odour: Vanilla, 1M: 
control n=5, P301S n=6; 3M: control n=6, P301S n=5; 5M: control n=7, P301S n=6. *p<0.05, 
** p<0.01, *** p<0.001 by two-tailed t-test analysis. Olfactory sensitivity test for social odour 
(C) Odour: female urine, control n=17, P301S n=12 (D) Time spent for investigation of 
female urine at low (Low, 0.0001% v/v) and high (High, 1% v/v) concentration by mice at 
4 months of age. There were significant deficits in response to highly diluted urine while 
there was a normal response towards high concentration of urine, control n=4, P301S n=5. 
White bar: Control, black bar: P301S. (E) Piriform cortex dependant odour-cross habituation 
test. Odours (n=3; limonene, heptanone, pentanol) were presented in blocks of three 
successive trials. The raw investigatory values were normalised to the maximum 
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investigatory duration during three trials for each odour. P301S tau mice displayed an 
abnormal pattern in habituation and dis-habituation towards novel scents. *p<0.05, ** p<0.01 
by three-way repeated measure ANOVA followed by post-hoc analysis using Tukey–
Kramer. Odour A, B, C represent limonene, heptanone, pentanol. Solid line: Control n=3, 
Dashed line: P301S n=5.  
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